These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

282 related articles for article (PubMed ID: 30194232)

  • 1. Functional characterization of reappearing B cells after anti-CD20 treatment of CNS autoimmune disease.
    Häusler D; Häusser-Kinzel S; Feldmann L; Torke S; Lepennetier G; Bernard CCA; Zamvil SS; Brück W; Lehmann-Horn K; Weber MS
    Proc Natl Acad Sci U S A; 2018 Sep; 115(39):9773-9778. PubMed ID: 30194232
    [TBL] [Abstract][Full Text] [Related]  

  • 2. B-cell activation influences T-cell polarization and outcome of anti-CD20 B-cell depletion in central nervous system autoimmunity.
    Weber MS; Prod'homme T; Patarroyo JC; Molnarfi N; Karnezis T; Lehmann-Horn K; Danilenko DM; Eastham-Anderson J; Slavin AJ; Linington C; Bernard CC; Martin F; Zamvil SS
    Ann Neurol; 2010 Sep; 68(3):369-83. PubMed ID: 20641064
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Late B cell depletion with a human anti-human CD20 IgG1κ monoclonal antibody halts the development of experimental autoimmune encephalomyelitis in marmosets.
    Kap YS; van Driel N; Blezer E; Parren PW; Bleeker WK; Laman JD; Craigen JL; 't Hart BA
    J Immunol; 2010 Oct; 185(7):3990-4003. PubMed ID: 20739677
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Anti-CD20 B-cell depletion enhances monocyte reactivity in neuroimmunological disorders.
    Lehmann-Horn K; Schleich E; Hertzenberg D; Hapfelmeier A; Kümpfel T; von Bubnoff N; Hohlfeld R; Berthele A; Hemmer B; Weber MS
    J Neuroinflammation; 2011 Oct; 8():146. PubMed ID: 22027448
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Autoreactive CD19+CD20- Plasma Cells Contribute to Disease Severity of Experimental Autoimmune Encephalomyelitis.
    Chen D; Ireland SJ; Davis LS; Kong X; Stowe AM; Wang Y; White WI; Herbst R; Monson NL
    J Immunol; 2016 Feb; 196(4):1541-9. PubMed ID: 26764035
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Efficient Distribution of a Novel Zirconium-89 Labeled Anti-cd20 Antibody Following Subcutaneous and Intravenous Administration in Control and Experimental Autoimmune Encephalomyelitis-Variant Mice.
    Migotto MA; Mardon K; Orian J; Weckbecker G; Kneuer R; Bhalla R; Reutens DC
    Front Immunol; 2019; 10():2437. PubMed ID: 31681317
    [No Abstract]   [Full Text] [Related]  

  • 7. Antigen-oriented T cell migration contributes to myelin peptide induced-EAE and immune tolerance.
    Zheng P; Fu H; Wei G; Wei Z; Zhang J; Ma X; Rui D; Meng X; Ming L
    Clin Immunol; 2016 Aug; 169():36-46. PubMed ID: 27327113
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Dynamic cross-regulation of antigen-specific effector and regulatory T cell subpopulations and microglia in brain autoimmunity.
    Martinez-Pasamar S; Abad E; Moreno B; Velez de Mendizabal N; Martinez-Forero I; Garcia-Ojalvo J; Villoslada P
    BMC Syst Biol; 2013 Apr; 7():34. PubMed ID: 23618467
    [TBL] [Abstract][Full Text] [Related]  

  • 9. T Cell Delivery of Nanoparticles-Bound Anti-CD20 Monoclonal Antibody: Successful B Cell Depletion in the Spinal Cord during Experimental Autoimmune Encephalomyelitis.
    Carnasciali A; Amoriello R; Bonechi E; Mazzoni A; Ravagli C; Doumett S; Cappiello L; D'Elios MM; Baldi G; Ballerini C
    J Neuroimmune Pharmacol; 2021 Jun; 16(2):376-389. PubMed ID: 32514635
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Subcutaneous anti-CD20 antibody treatment delays gray matter atrophy in human myelin oligodendrocyte glycoprotein-induced EAE mice.
    Pol S; Liang S; Schweser F; Dhanraj R; Schubart A; Preda M; Sveinsson M; Ramasamy DP; Dwyer MG; Weckbecker G; Zivadinov R
    Exp Neurol; 2021 Jan; 335():113488. PubMed ID: 32991933
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Depletion of CD20 B cells fails to inhibit relapsing mouse experimental autoimmune encephalomyelitis.
    Sefia E; Pryce G; Meier UC; Giovannoni G; Baker D
    Mult Scler Relat Disord; 2017 May; 14():46-50. PubMed ID: 28619431
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Obinutuzumab-Induced B Cell Depletion Reduces Spinal Cord Pathology in a CD20 Double Transgenic Mouse Model of Multiple Sclerosis.
    Breakell T; Tacke S; Schropp V; Zetterberg H; Blennow K; Urich E; Kuerten S
    Int J Mol Sci; 2020 Sep; 21(18):. PubMed ID: 32962135
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Myelin-reactive antibodies initiate T cell-mediated CNS autoimmune disease by opsonization of endogenous antigen.
    Kinzel S; Lehmann-Horn K; Torke S; Häusler D; Winkler A; Stadelmann C; Payne N; Feldmann L; Saiz A; Reindl M; Lalive PH; Bernard CC; Brück W; Weber MS
    Acta Neuropathol; 2016 Jul; 132(1):43-58. PubMed ID: 27022743
    [TBL] [Abstract][Full Text] [Related]  

  • 14. T cell-depleted splenocytes from mice pre-immunized with neuroantigen in incomplete Freund's adjuvant involved in protection from experimental autoimmune encephalomyelitis.
    Zheng H; Zhang H; Liu F; Qi Y; Jiang H
    Immunol Lett; 2014; 157(1-2):38-44. PubMed ID: 24220208
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Anti-CD20 treatment depletes B-cells in blood and lymphatic tissue of cynomolgus monkeys.
    Schröder C; Azimzadeh AM; Wu G; Price JO; Atkinson JB; Pierson RN
    Transpl Immunol; 2003; 12(1):19-28. PubMed ID: 14551029
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Endogenous opioid inhibition of proliferation of T and B cell subpopulations in response to immunization for experimental autoimmune encephalomyelitis.
    McLaughlin PJ; McHugh DP; Magister MJ; Zagon IS
    BMC Immunol; 2015 Apr; 16():24. PubMed ID: 25906771
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Regulatory B cells inhibit EAE initiation in mice while other B cells promote disease progression.
    Matsushita T; Yanaba K; Bouaziz JD; Fujimoto M; Tedder TF
    J Clin Invest; 2008 Oct; 118(10):3420-30. PubMed ID: 18802481
    [TBL] [Abstract][Full Text] [Related]  

  • 18. CNS Autoimmune Responses in BCMA-Deficient Mice Provide Insight for the Failure of Atacicept in MS.
    Kumar G; Maria Z; Kohli U; Agasing A; Quinn JL; Ko RM; Zamvil SS; Axtell RC
    Neurol Neuroimmunol Neuroinflamm; 2021 May; 8(3):. PubMed ID: 33649164
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The different clinical effects of anti-BLyS, anti-APRIL and anti-CD20 antibodies point at a critical pathogenic role of γ-herpesvirus infected B cells in the marmoset EAE model.
    Anwar Jagessar S; Fagrouch Z; Heijmans N; Bauer J; Laman JD; Oh L; Migone T; Verschoor EJ; 't Hart BA
    J Neuroimmune Pharmacol; 2013 Jun; 8(3):727-38. PubMed ID: 23508625
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Low-Dose Subcutaneous Anti-CD20 Treatment Depletes Disease Relevant B Cell Subsets and Attenuates Neuroinflammation.
    Huck C; Leppert D; Wegert V; Schmid C; Dunn R; Weckbecker G; Smith PA
    J Neuroimmune Pharmacol; 2019 Dec; 14(4):709-719. PubMed ID: 31435856
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.